1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

GSK Begins Shipping Fluviral Ahead of Canada’s 2025

10 Sep 2025
Admin
News Article

GSK Begins Shipping Fluviral Ahead of Canada’s 2025–26 Flu Season

GSK Canada (GlaxoSmithKline Inc.) has started shipping its trivalent seasonal influenza vaccine, Fluviral, to provinces across the country in preparation for the 2025–26 flu season.

Protecting Canadians Against Influenza

Fluviral is approved for use in adults and children over six months of age.
It protects against influenza virus types A and B included in the vaccine.
Annual vaccination remains the most effective way to reduce flu risks, according to Health Canada.
Each year, influenza leads to:
- 12,000+ hospitalizations
- 3,500 deaths
- Ranking among Canada’s top 10 leading causes of death.

The Public Health Agency of Canada recommends yearly vaccination for everyone six months and older, unless contraindicated.

Made in Quebec for Canadians

Fluviral is manufactured at GSK’s Ste-Foy, Quebec facility, which has supplied Canadians with flu vaccines since 1997.
The site produces the majority of Canada’s seasonal flu vaccine supply.
In the event of a pandemic, it serves as the country’s primary supplier of influenza vaccine.

2025–26 WHO Strain Recommendations

Each year, the World Health Organization (WHO) reviews circulating strains and recommends vaccine composition.
For egg-based vaccines in the Northern Hemisphere (2025–26), WHO advised including:

A/Victoria/4897/2022 (H1N1)pdm09-like virus
A/Croatia/10136RV/2023 (H3N2)-like virus
B/Austria/1359417/2021 (B/Victoria lineage)-like virus

Fluviral’s composition for this season follows these recommendations.

Who Is at Higher Risk?

Although anyone can get the flu, complications are more common in:

Children under six
Adults 65+
Indigenous Peoples
Pregnant women
People in congregate care settings
Individuals with chronic conditions such as asthma, diabetes, or heart disease

About Fluviral

Type: Trivalent, split-virion influenza vaccine
Use: Active immunization against influenza A and B
Age group: Adults and children over six months

GSK’s Broader Mission

GSK describes its purpose as uniting science, technology, and talent to get ahead of disease together.